Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Otonomy Inc is a biotechnology business based in the US. Otonomy shares (OTIC) are listed on the NASDAQ and all prices are listed in US Dollars. Otonomy employs 51 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $0.30 |
|---|---|
| 52-week range | $0.24 - $2.59 |
| 50-day moving average | $0.55 |
| 200-day moving average | $1.72 |
| Wall St. target price | $6.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.78 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.295 from 2022-09-30
| 1 week (2022-09-26) | 5.92% |
|---|---|
| 1 month (2022-09-02) | -16.03% |
| 3 months (2022-07-01) | -85.75% |
| 6 months (2022-04-01) | -87.50% |
| 1 year (2021-10-01) | -83.52% |
|---|---|
| 2 years (2020-10-02) | -93.36% |
| 3 years (2019-10-03) | 2.18 |
| 5 years (2017-10-03) | 3.5 |
| Gross profit TTM | $-245,000 |
|---|---|
| Return on assets TTM | -34.62% |
| Return on equity TTM | -96.77% |
| Profit margin | 0% |
| Book value | $0.56 |
| Market capitalisation | $16.9 million |
TTM: trailing 12 months
We're not expecting Otonomy to pay a dividend over the next 12 months.
Over the last 12 months, Otonomy's shares have ranged in value from as little as $0.24 up to $2.59. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Otonomy's is 1.4778. This would suggest that Otonomy's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Otonomy, Inc. , a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.